Diridavumab

Diridavumab is a monoclonal anti-HA stalk antibody. Diridavumab stabilizes the prefusion HA structure and prevents pH-dependent fusion of cellular and viral membranes in endosomes. Diridavumab can be used in research of H2 influenza virus[1].

Signaling Pathways >> Anti-infection >> Influenza Virus

Research Areas >> Infection

Diridavumab (CR6261; 500 μg/mL) 分别以 39.4 μg/mL 和 176.8 μg/mL 的浓度中和 AA60 和 Sw06[1]。

Diridavumab (CR6261; 1.7-15 mg/kg; i.p.; 携带 H2 流感病毒的 BALB/c 小鼠) 以剂量依赖性方式保护小鼠免受致命的 H2 流感病毒的侵害[1]。 Animal Model: BALB/c mice with H2 influenza virus[1] Dosage: 1.7, 5, or 15 mg/kg Administration: Intraperitoneal injection Result: Prevented mortality and decreased the percent weight loss. Decreased viral load, altered antigen distribution, and reduced the severity of airway inflammation.

[1]. Sutton TC, et, al. In Vitro Neutralization Is Not Predictive of Prophylactic Efficacy of Broadly Neutralizing Monoclonal Antibodies CR6261 and CR9114 against Lethal H2 Influenza Virus Challenge in Mice. J Virol. 2017 Nov 30;91(24):e01603-17.